HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2025 earnings estimates for Altimmune in a research report issued on Thursday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.33) per share for the quarter, up from their prior estimate of ($0.34). HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune's Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.24) EPS, Q1 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.37) EPS.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the company earned ($0.34) earnings per share.

Separately, William Blair reiterated a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $20.20.

Altimmune Trading Down 3.5%

Shares of Altimmune stock opened at $5.58 on Monday. Altimmune has a twelve month low of $3.55 and a twelve month high of $11.16. The firm has a market capitalization of $429.74 million, a PE ratio of -3.60 and a beta of 1.13. The firm's 50-day moving average price is $5.11 and its 200 day moving average price is $6.56.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. raised its stake in Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after purchasing an additional 1,378,854 shares during the period. RFG Advisory LLC acquired a new stake in shares of Altimmune during the 1st quarter worth approximately $1,622,000. Nuveen LLC purchased a new stake in shares of Altimmune during the 1st quarter valued at approximately $1,304,000. Invesco Ltd. lifted its holdings in Altimmune by 679.2% in the fourth quarter. Invesco Ltd. now owns 247,086 shares of the company's stock valued at $1,781,000 after acquiring an additional 215,375 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Altimmune by 139.8% in the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company's stock valued at $2,492,000 after acquiring an additional 201,484 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company's stock.

Insider Buying and Selling

In related news, CFO Gregory L. Weaver bought 10,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.10% of the stock is currently owned by company insiders.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.